Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
$18.31
-2.9%
$15.87
$9.57
$30.41
$2.60B0.931.56 million shs1.45 million shs
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$46.47
+0.4%
$38.69
$21.72
$46.80
$8.79B1.152.53 million shs2.19 million shs
Evotec SE stock logo
EVTCY
Evotec
$4.17
+0.5%
$4.13
$14.22
$26.57
$1.38B0.982,407 shs22,104 shs
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
$68.49
$68.47
$21.65
$73.02
$4.62B0.452.07 million shs74 shs
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
$25.01
-0.4%
$14.22
$6.48
$37.38
$311.42M0.94502,718 shs1.21 million shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
-2.92%+9.12%+9.38%+55.30%-31.73%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
+0.43%+6.33%+19.00%+37.04%+75.03%
Evotec SE stock logo
EVTCY
Evotec
+0.48%-0.71%+0.97%+36.27%-18.55%
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
0.00%0.00%0.00%0.00%0.00%
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
-0.36%+1.46%+161.88%+169.93%+25.36%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
3.7421 of 5 stars
3.42.00.03.41.82.50.0
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
4.5841 of 5 stars
4.51.00.03.92.53.30.6
Evotec SE stock logo
EVTCY
Evotec
N/AN/AN/AN/AN/AN/AN/AN/A
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
4.1204 of 5 stars
3.42.00.04.23.22.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
2.75
Moderate Buy$43.71138.75% Upside
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
3.00
Buy$60.2129.58% Upside
Evotec SE stock logo
EVTCY
Evotec
0.00
N/AN/AN/A
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
0.00
N/AN/AN/A
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
2.86
Moderate Buy$88.33253.19% Upside

Current Analyst Ratings Breakdown

Latest ARWR, GBT, EVTCY, BBIO, and NKTR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/11/2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$58.00 ➝ $67.00
7/9/2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$60.00
7/8/2025
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$60.00 ➝ $85.00
6/30/2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$67.00 ➝ $76.00
6/25/2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$50.00 ➝ $54.00
6/24/2025
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy$60.00 ➝ $100.00
6/24/2025
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$120.00
6/17/2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$49.00
6/9/2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$53.00 ➝ $56.00
5/20/2025
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$80.00 ➝ $80.00
5/13/2025
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$21.00 ➝ $17.00
(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
$3.55M712.28N/AN/A$1.54 per share11.89
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$221.90M39.76N/AN/A($7.71) per share-6.03
Evotec SE stock logo
EVTCY
Evotec
$572.16M2.41$0.04 per share105.53$2.52 per share1.65
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
$194.75M23.73N/AN/A$3.05 per share22.46
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
$98.43M3.15N/AN/A$4.94 per share5.06
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
-$599.49M-$1.40N/AN/A22.18N/A-45.33%-12.49%8/6/2025 (Estimated)
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$535.76M-$3.53N/AN/AN/A-524.25%N/A-94.43%7/30/2025 (Estimated)
Evotec SE stock logo
EVTCY
Evotec
$7.14M$0.4110.17N/A20.85%16.02%7.81%N/A
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
-$303.09M-$5.01N/AN/AN/A-137.30%-170.37%-39.24%N/A
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
-$118.96M-$9.60N/AN/AN/A-152.49%-329.54%-55.24%8/6/2025 (Estimated)

Latest ARWR, GBT, EVTCY, BBIO, and NKTR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$0.50N/AN/AN/AN/AN/A
5/12/2025Q2 2025
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
-$0.06$2.75+$2.81$2.75$116.27 million$542.71 million
5/8/2025Q1 2025
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
-$2.70-$3.30-$0.60-$0.24$15.61 million$10.46 million
4/29/2025Q1 2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$1.00-$0.88+$0.12-$0.88$57.14 million$36.74 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
N/AN/AN/AN/AN/A
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/AN/AN/AN/AN/A
Evotec SE stock logo
EVTCY
Evotec
N/AN/AN/AN/AN/A
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
N/AN/AN/AN/AN/A
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
0.31
5.15
5.15
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/A
4.57
4.54
Evotec SE stock logo
EVTCY
Evotec
0.53
2.57
2.50
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
4.92
6.88
6.17
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
N/A
3.24
3.24
CompanyEmployeesShares OutstandingFree FloatOptionable
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
400138.10 million132.16 millionOptionable
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
400189.88 million155.32 millionOptionable
Evotec SE stock logo
EVTCY
Evotec
4,200330.22 millionN/ANot Optionable
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
45767.48 million64.17 millionOptionable
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
22012.41 million11.76 millionOptionable

Recent News About These Companies

Q2 EPS Forecast for Nektar Therapeutics Lowered by Analyst
Q2 EPS Estimate for Nektar Therapeutics Reduced by Analyst

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Arrowhead Pharmaceuticals stock logo

Arrowhead Pharmaceuticals NASDAQ:ARWR

$18.31 -0.55 (-2.92%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$18.27 -0.04 (-0.22%)
As of 07/11/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

BridgeBio Pharma stock logo

BridgeBio Pharma NASDAQ:BBIO

$46.47 +0.20 (+0.43%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$46.30 -0.17 (-0.36%)
As of 07/11/2025 07:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Evotec stock logo

Evotec OTCMKTS:EVTCY

$4.17 +0.02 (+0.48%)
As of 07/10/2025

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.

Global Blood Therapeutics stock logo

Global Blood Therapeutics NASDAQ:GBT

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.

Nektar Therapeutics stock logo

Nektar Therapeutics NASDAQ:NKTR

$25.01 -0.09 (-0.36%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$24.74 -0.28 (-1.10%)
As of 07/11/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.